In Blenrep, GSK sees a blockbuster candidate in a therapeutic area where none of its approved drugs have that status. The company forecasts that Blenrep's potential peak sales could top 3 billion ...

GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine ...

GSK announces phase I/II therapeutic herpes simplex virus vaccine trial fails to meet the study’s primary efficacy objective: London, UK Thursday, September 12, 2024, 09:00 Hrs ...

Drugmaker GSK said on Wednesday that primary objective data analysts from a phase II trial of its early-stage therapeutic ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target ...

An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...

including European Union/European Economic Area and US. Regulatory reviews in multiple countries are ongoing. The proposed trade name remains subject to regulatory approval in other markets. The GSK ...

"Given the unmet medical need and burden associated with genital herpes, innovation in this area is still needed. GSK intends to evaluate the totality of all these data and other studies to progress ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

The vaccine candidate, GSK3943104, was aimed at providing a new therapeutic option for ... innovation in this area is still needed. GSK intends to evaluate the totality of all these data and ...